Key facts
- Inherent Biosciences’s last known valuation is $18.1M (Sep 2022).
- It has raised $9.8M across 1 recorded rounds; the latest was Seed Round ($1.5M) in Aug 2022.
- Notable investors include US National Science Foundation, Endless Frontier Labs, Kickstart (US), Cadron Capital Partners, Samothrace Partners — 18 tracked in total.
- Inherent Biosciences has filed 1 Form D with the SEC, most recently May 2023 ($1.5M sold to 12 investors).
- Status: Privately Held (backing).
Investors
18+- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Inherent Biosciences
Funding rounds
1 roundsAbout Inherent Biosciences
Developer of an epigenetic medicine platform designed to tackle health issues by overhauling the trial-and-error methodology. The company's platform detects dysregulation across multiple genes and related pathways to pioneer a new category of diagnostics and therapeutics that leverage epigenetics along with lifestyle effects on the probability of a positive reproduction, enabling doctors and physicians to guide patients with complex diseases.
- Sector
- Healthcare
- HQ
- Salt Lake City, UT, United States
- Founded
- 2019
- Employees
- 15
- Website
- inherentbio.com/
- Ownership
- Privately Held (backing)
Inherent Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inherent Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inherent Biosciences in its N-PORT filings yet. We sweep new filings monthly.